Language
Grade: Pharmaceutical Grade
Factory Location: Shenyang Liaoning China
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
INLEUSIN is an important lymphokine, for the proliferation of cytotoxic T cell, natural killer cell and lymphokine-activated killer cell and enhancing their cytopathic activity. It also accelerates the lymphocyte excreting antibody and interferon, exerting antiviral, anti-tumor activity and enhancing human immuno-regulation activity.
Indication:
INLEUSIN mainly is indicated for treatment of metastatic renal cell carcinoma (RCC), malignant melanoma and control of carcinomatous hydrothorax and hydroperitoneum.
INLEUSIN mainly is indicated for treatment of metastatic renal cell carcinoma (RCC), malignant melanoma and control of carcinomatous hydrothorax and hydroperitoneum.
